<DOC>
	<DOCNO>NCT00110006</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , positron emission tomography ( PET ) use fludeoxyglucose F 18 , may help learn well chemotherapy work kill cancer cell allow doctor plan good treatment . Comparing result diagnostic procedure do , , chemotherapy may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This clinical trial study positron emission tomography use fludeoxyglucose F 18 see well work predict response treatment patient receive rituximab combination chemotherapy newly diagnose non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Positron Emission Tomography Using Fludeoxyglucose F 18 Predicting Response Treatment Patients Who Are Receiving Rituximab Combination Chemotherapy Newly Diagnosed Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine positive negative predictive value early positron emission tomography ( PET ) scan use fludeoxyglucose F 18 term probability patient newly diagnose intermediate- high-grade non-Hodgkin 's lymphoma achieve achieve complete remission , treatment 1 course rituximab combination chemotherapy comprise cyclophosphamide , doxorubicin , vincristine , prednisone . - Determine event free overall survival patient early positive negative PET scan treat regimen . - Determine predictive value early PET scan response ratio continuous variable term response therapy ( assessed end therapy ) , disease-free survival , overall survival , patient treat regimen . - Correlate International Prognostic Index score presentation early PET scan result overall outcome patient treat regimen . - Correlate degree neutropenia 7 10 day first course treatment rituximab combination chemotherapy PET scan response pre-treatment blood CD34-positive cell concentration patient . OUTLINE : This multicenter study . Patients receive fludeoxyglucose F 18 ( ^18FDG ) IV . Beginning 1 hour later , patient undergo whole-body positron emission tomography ( PET ) scan . Patients also undergo conventional radiographic stag disease . Patients receive standard R-CHOP ( alternative regimen ) comprise rituximab IV 3-6 hour , cyclophosphamide IV 30 minute , doxorubicin IV 5 minute , vincristine IV 5 minute day 1 oral prednisone daily day 1-5 . Treatment repeat every 14-21 day 4 course absence unacceptable toxicity . Patients undergo repeat ^18FDG-PET scanning day 7-10 course 1 , course 3 4 , completion R-CHOP . Patients also undergo radiographic restaging disease course 3 4 completion R-CHOP . After completion study treatment , patient follow every 3-4 month 2 year , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose nonHodgkin 's lymphoma ( NHL ) Intermediate highgrade disease Stage IIV disease Any follow subtypes allow : Diffuse large Bcell lymphoma Anaplastic large cell lymphoma Mantle cell lymphoma Grade 3 follicular lymphoma Mediastinal Bcell lymphoma The following subtypes allow : Lymphoblastic lymphoma Mycosis fungoides/Sézary 's syndrome HTLV1 associate Tcell leukemia lymphoma Primary CNS lymphoma HIVassociated lymphoma Transformed lymphoma Burkitt 's lymphoma Adequate staging lymphoma follow method : CT scan MRI affect site Unilateral bilateral bone marrow biopsy Positive pretreatment positron emission tomography ( PET ) scan Lumbar puncture Radiographically measurable disease PET scan Any International Prognostic Index risk category allow No prior diagnosis another hematologic malignancy NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3* Platelet count ≥ 75,000/mm^3* NOTE : *Unless due NHL Hepatic Bilirubin ≤ 2.0 mg/dL* ( exclude Gilbert 's disease ) NOTE : *Unless due NHL Renal Creatinine ≤ 2.0 mg/dL ( unless due NHL ) Cardiovascular Ejection fraction ≥ 45 % echocardiogram MUGA Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No malignancy within past 5 year except superficial nonmelanoma skin cancer carcinoma situ cervix No serious comorbid disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior rituximab NHL No concurrent filgrastim [ GCSF ] course 1 study treatment except patient &gt; 70 year age OR patient active infection Chemotherapy No prior chemotherapy NHL Endocrine therapy No prior steroids NHL Radiotherapy No prior radiotherapy NHL Concurrent consolidation radiotherapy sit bulky disease allow discretion attend physician Surgery Not specify Other No prior treatment NHL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>